Myriad Genetics
在场
是其中之一......
Myriad Genetics 是一家在股票代码 MYGN (US) 下上市的公司。
Myriad Genetics 在 2 个国家有直接业务。Myriad Genetics 拥有 4家子公司，其中包括 GeneSight、Myriad Genetics Europe 和 Myriad RBM。
他们在：
高管
查看带有其 43 名主要高管的组织结构图
Myriad Genetics 搜索最多的简介
- Paul Diaz, Director, President and Chief Executive Officer
- Heiner Dreismann, Director
- Lee Newcomer, Director
高管在Myriad Genetics变化
- Jennifer Fox已作为Chief Legal Officer加入公司 (新闻发布的2024八月1号).
创建提醒
跟踪 Myriad Genetics 的高管变动
药店
Myriad Genetics 拥有 1,842 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Stemtech and Seacret Direct have announced they will merge (公布2024十一月22号)..
- BeiGene将改名为BeOne Medicines。 (公布2024十一月15号).
- GlycoMimetics and Crescent Biopharma have announced they will merge (公布2024十一月15号)..
药店 行业的其他推荐联系人
消息
Myriad Genetics 的最新新闻稿
- Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch
- Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance
- Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing
- Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024
- Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access
- News Release Detail | Myriad GeneticsClose this dialogClose Cookie Preferences
- News Release Detail | Myriad GeneticsClose this dialogClose Cookie Preferences
- News Release Detail | Myriad GeneticsClose this dialogClose Cookie Preferences
- News Release Detail | Myriad GeneticsClose this dialogClose Cookie Preferences
- News Release Detail | Myriad GeneticsClose this dialogClose Cookie Preferences
- View more press releases Close
通过电子邮件
